Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.60 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6575282 | 0.83 | LMNA (0.59) | CHRM2CHRM1BLMSMN1; SMN2CHRM3 | |
| Tematropium SCHEMBL29388056 | 0.82 | CHRM2 (0.67) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Tematropium SCHEMBL667952 | 0.76 | CHRM2 (0.58) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| SCHEMBL6574169 | 0.76 | CHRM2 (0.50) | CHRM2CHRM1BLMAPOBEC3AAPOBEC3G | |
| Methylhomatropine SCHEMBL30516140 | 0.75 | CHRM2 (1.00) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylhomatropine SCHEMBL17179980 | 0.75 | CHRM2 (1.00) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylhomatropine SCHEMBL16784195 | 0.75 | CHRM2 (1.00) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylatropine SCHEMBL824874 | 0.75 | CHRM2 (1.00) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylatropine SCHEMBL34463463 | 0.75 | CHRM2 (1.00) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylhomatropine SCHEMBL77827 | 0.74 | CHRM2 (0.97) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383730-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | Aryx Therapeutics (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002096855-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | ARYX THERAPEUTICS (US) | 2002-12-05 | — | — | WO | claimed |
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | ARYX THERAPEUTICS | 2002-11-14 | — | — | US | claimed |
| EP-1383730-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | Aryx Therapeutics (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002096855-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | ARYX THERAPEUTICS (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | ARYX THERAPEUTICS | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM1 9/4885PABPC1 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.